INTRODUCTION
The cytochrome P450s are hemoproteins that play critical roles in the bioactivation and detoxication of a wide variety of xenobiotic substances. The enzymes are encoded by a superfamily of genes. The term "cytochrome P450" originates from the observation that the reduced state of the proteins form complexes with carbon monoxide that exhibit absorbance maxima at 450 nm (Omura and Sato, 1964) . The P450 enzymes are now referred to as heme-thiolate proteins. P450s have been characterized in many species of organisms, including bacteria, fungi, plants, fish, and mammalian systems (Nebert and McKinnon, 1994) . In mammalian cells, P450s are localized predominantly in the smooth endoplasmic reticulum of the cell and are entirely distinct from the cytochrome proteins that comprise the mitochondrial electron-transport function.
Currently, Ͼ700 P450s have been characterized, inclusive of the many different species of organisms that have been studied (Nelson et al., 1996) . Based primarily on sequence similarities, a standardized nomenclature has been adopted that categorizes the individual P450s into respective families and subfamilies. P450 proteins exhibiting Ͼ40% similarity in protein sequence are classified within the same family; proteins exhibiting Ͼ55% sequence similarity are grouped into the same subfamily (Nebert and McKinnon, 1994; Nelson et al., 1996) . Although the catalog is updated regularly, the current P450 nomenclature and classification scheme was most recently reviewed in 1996 (Nelson et al., 1996) . The purpose of this current review is to very briefly highlight some of the more important mammalian P450s with respect to their expression, inducibility and inhibition character, and substrate preferences, especially as they relate to human toxicology. Due to this limited scope, it is impossible to thoroughly reference all the important and relevant literature pertaining to this topic. The reader is referred to other recent reviews for more detailed information (Dogra et al., 1998; Meyer and Zanger, 1997; Pelkonen and Raunio, 1997; Rendic and Di-Carlo, 1997) . Information from these and other references has been used as source material to compile the contents of Table 1 , summarizing some of the salient features of several relevant P450s.
CYP1 FAMILY
The CYP1 family includes two subfamilies, CYP1A and CYP1B (Nebert and McKinnon, 1994) . The CYP1A family members, CYP1A1 and CYP1A2 have been well characterized and historically are linked to the aryl hydrocarbon receptor as inducible genes (Dogra et al., 1998; Gonzalez et al., 1993) . The CYP1A enzymes bioactivate several procarcinogens. These include benzo [a] pyrene and other polyaromatic hydrocarbons (for CYP1A1) and, aromatic amines, such as 2-acetylaminofluorene, heterocyclic amines, and aflatoxin B1 (for CYP1A2) (Eaton et al., 1995; Gallagher et al., 1996; Pelkonen and Raunio, 1997; Rendic and Di-Carlo, 1997) . CYP1A1 is expressed in many tissues, but typically only after induction with TCDD or other Ah receptor ligands. In contrast, CYP1A2 is primarily expressed in the liver at significant constitutive levels and is highly inducible in this tissue via the Ah receptor pathway (Dogra et al., 1998; Gonzalez et al., 1993) . Theophylline, caffeine, and phenacetin are useful in vivo substrate probes for determining CYP1A activity status in humans Nakajima et al., 1994) . (Guengerich et al., 1995) . Furafylline is a highly specific mechanism-based inhibitor of CYP1A2 (Eaton et al., 1995; Gallagher et al., 1996) .
CYP1B1 is a more recently characterized member of the CYP1 family. CYP1B1 is constitutively expressed in most tissues but also inducible through the Ah receptor pathway. CYP1B1 is involved in the metabolism of endogenous estrogens, as well as active in the biotransformation of heterocyclic amines found in charcoal broiled meats (Crofts et al., 1997) . 
CYP2 FAMILY
The CYP2 family is the largest and most diverse of the CYP families and is comprised of several subfamilies, including CYP2A, CYP2B, CYP2C, CYP2D, and CYP2E (Nelson et al., 1996) . The characteristics of the individual CYP2 subfamilies are discussed below.
CYP2A. The CYP2A subfamily consists of Ͼ10 different members from various species (Fernandez and Gonzalez, 1995) . Of these, CYP2A1, CYP2A2, and CYP2A3 are expressed in rats, and CYP2A6 and CYP2A7 are expressed in humans. CYP2A6 demonstrates activity with several carcinogenic substrates, including aflatoxin B1, N-nitrosodiethylamine, and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone Rendic and DiCarlo, 1997; and Parkinson, 1996 . The abbreviations used in the table are (NNK, a tobacco-specific nitrosamine) (Gonzalez and Gelboin, 1994) . These CYP2A family members are expressed primarily in the liver. CYP2A6 is inducible by barbiturates. Coumarin 7-hydroxylation is routinely used as a substrate probe to measure CYP2A6 activity (Li et al., 1997) .
CYP2B. The CYP2B subfamily is comprised of ϳ17 different members, identified in several different species. CYP2B1 and CYP2B2 are the primary members expressed in rats, whereas CYP2B6 is expressed at low levels in human liver (Mimura et al., 1993) . In rodents, enzymes from this subfamily are typically inducible by phenobarbital and other barbiturates, and are inhibited by metyrapone. CYP2B members are involved in the metabolism of a variety of pharmaceutical compounds, including amphetamines and benzodiazepines (Rendic and Di-Carlo, 1997; Yang et al., 1998 ). CYP2B6 appears to bioactivate 6-aminochrysene and the antineoplastic drugs cyclophosphamide and ifosfamide (Code et al., 1997; Ekins et al., 1997; Parkinson, 1996) . Pentoxyresorufin and benzyloxyresorufin are often used as substrate probes to measure CYP2B activity in vitro (Rendic and Di-Carlo, 1997) .
CYP2C. This subfamily consists of CYP2C8, CYP2C9, CYP2C18, and CYP2C19 in humans, although a total of ϳ40 different members have been identified from several species, including rats, rabbits, mice, monkeys, goats, pigs, and dogs. CYP2C9 accounts for approximately 17-20% of the total P450 content in human livers (Parkinson, 1996) . The enzymes of the CYP2C subfamily are responsible for the metabolism of a wide variety of compounds, including, S-mephenytoin, phenytoin, tolbutamide, S-warfarin, and non-steroidal anti-inflammatory agents (Rahman et al., 1994; Steward et al., 1997) . Phenytoin, mephenytoin, and tolbutamide are used as common in vitro substrate probes to measure CYP2C activity. Rifampin appears to be an effective inducer of CYP2C family members. No common toxicological substances have been clearly identified as important substrates of these P450s (Parkinson, 1996) .
CYP2D.
Over 20 different members of the CYP2D subfamily have been identified in several different species. Whereas 5 different CYP2D subfamily members are expressed in the rat, humans express 1 major CYP2D form, CYP2D6. The human CYP2D7 and CYP2D8 genes have been characterized but do not appear to be expressed. CYP2D6 accounts for ϳ2% of the total P450 content in human livers (Parkinson, 1996) . The enzyme does not appear to be inducible but is constitutively active in metabolizing a number of different pharmaceutical agents containing basic nitrogen atoms, including sparteine, debrisoquine, dextromethorphan, and codeine. Dextromethorphan has been used as a substrate probe for CYP2D activity measurements, and as a tool to phenotype individuals. Some of the more clinically relevant inhibitors of CYP2D6 include quinidine, quinine, fluoxetine, and paroxetine. NNK appears to be a xenobiotic substrate for CYP2D6 (Daly et al., 1996; Gonzalez and Gelboin, 1994) . CYP2E. CYP2E1 is the predominant member of the CYP2E subfamily, although CYP2E2 also has been identified in rabbits. CYP2E1 accounts for ϳ7% of the total P450 content in the human liver, although its expression has been detected in other tissues (Parkinson, 1996) . CYP2E1 is responsible for the metabolism and potential bioactivation of a number of low-molecular-weight pharmaceutical and other xenobiotic compounds, including acetaminophen, ethanol, isoniazid, halogenated anesthetics, acetone, and benzene (Lee et al., 1996; Lieber, 1997) . Chlorzoxazone and p-nitrophenol are routinely used as substrate probes to measure CYP2E1 activity, although chlorzoxazone can also be metabolized by CYP1A2 (Ono et al., 1995) . The enzyme is inducible by ethanol, acetone, isoniazid, and by starvation in animal models (Lieber, 1997) . Inhibition of CYP2E1 is observed upon treatment with diethyldithiocarbamate, isothiocyanates, and 4-methyl pyrazole (Lieber, 1997; Rendic and Di-Carlo, 1997 ).
CYP3 FAMILY
The CYP3 family accounts for the metabolism of ϳ50% of the currently used pharmaceutical agents (Parkinson, 1996) . Approximately 22 different CYP3A subfamily members have been identified in many different species, including humans, rabbits, macaques, hamsters, rats, mice, and dogs (Nelson et al., 1996) .
CYP3A. The CYP3A subfamily members account for ϳ30 -40% of the total P450 content in human livers (Parkinson, 1996; Rendic and Di-Carlo, 1997) . The relevant human CYP3A members include CYP3A4, CYP3A5, and CYP3A7. CYP3A4 and CYP3A5 are expressed in the liver and in the intestinal mucosa (Rendic and Di-Carlo, 1997) . CYP3A5 is a polymorphic form and is expressed in about 30% of human livers and 70% of intestines. CYP3A7 is primarily a fetal form of CYP3A, although it has been detected in ϳ25% of the adult livers surveyed. The enzymes of the CYP3A subfamily are inducible by rifampin and barbiturates, and to a lesser extent by carbamazepine, phenytoin, and dexamethasone (Thummel and Wilkinson, 1998) . This subfamily of enzymes is responsible for the metabolism of a large and diverse group of substrates, as indicated in Table 1 . Nifedipine, midazolam, and testosterone-6␤-hydroxylation are common substrate probes used to measure CYP3A activity (Wilkinson, 1996) . These enzymes are inhibited by a wide variety of compounds, including triacetyloleandomycin (TAO), macrolide antibiotics, the azole antifungal agents, and competitively by a number of CYP3A substrates (Thummel and Wilkinson, 1998; Wilkinson, 1996) . Several CYP3A substrates of toxicological relevance include aflatoxin B1, 1-nitropyrene, and 6-aminochrysene (Parkinson, 1996; Rendic and Di-Carlo, 1997) .
The CYP4 family consists of 11 subfamilies (CYP4A-CYP4M) (Simpson, 1997) , with the CYP4A subfamily perhaps the most prominently studied.
CYP4A. The CYP4A subfamily is of interest in toxicology, due to its inducibility by multiple chemicals, including agents used as plasticizers, herbicides, and solvents, e.g., di-(2-ethylhexyl) phthalate, 2,4-dichlorophenoxyacetic acid, and trichloroethylene, respectively (Simpson, 1997) . Although endogenous compounds such as fatty acids undergo oxidation by CYP4A enzymes, no commonly known environmental chemicals appear to be metabolized by this pathway (Parkinson, 1996) . The CYP4A subfamily also may be involved in the metabolism of arachidonic acid leading to the production of physiologically important derivatives involved in processes such as blood flow in the kidney, cornea, and brain (Simpson, 1997) . The induction of the CYP4A system is mediated by the peroxisomal proliferator receptor ␣, a nuclear receptor that belongs to the superfamily of receptors that includes estrogen, thyroid, glucocorticoid, retinoic acid, and a large number of "orphan" receptors (Gonzalez, 1997; Simpson, 1997) . These receptors undergo dimerization with the retinoic acid X receptor, to activate gene expression at responsive gene loci (Gonzalez, 1997; Palmer et al., 1998) . Exposure to peroxisome proliferator agents appears to be associated with the development of hepatocarcinogenesis in rodents, although not in humans (Palmer et al., 1998) .
GENETIC POLYMORPHISM
Genetic variation within the human cytochrome P450 system has been well documented, and allelic variants for most of the P450 genes have been identified. Many of the genetic variants characterized involve base substitutions in non-coding regions of the respective genes, e.g., within introns or flanking regions. The functional importance of these allelic variants is largely still being determined. However, genetic variants resulting in clear structural and functional character have also been characterized within the population. The relative frequencies of the respective alleles often vary with ethnic origin. One of the best characterized P450 genes exhibiting polymorphic character is CYP2D6, with Ͼ17 allelic variants identified thus far, and with several resulting in poor metabolizer status (Daly et al., 1996; Meyer and Zanger, 1997) . Genetically programmed differences in an individual's P450 expression profile will likely represent an important risk determinant of chemical toxicity. Although P450 polymorphism is a fascinating and important area of current study, the topic is beyond the scope of this article. The reader is referred to recent reviews on this subject for further detailed information (Meyer and Zanger, 1997; Daly, 1995; Pelkonen and Raunio, 1997; Nebert, 1997) .
It is clear that the cytochrome P450 enzymes play pivotal roles with respect to xenobiotic metabolism. A great deal of progress has been made in characterizing the P450s, with respect to their contributions toward human toxicology. Further developments, using innovative biochemical and clinical approaches, coupled with transgenic models and molecular genetic analyses, continue to add to our knowledge base in this area. An important goal of these studies is to identify the key risk factors that dictate toxicological responses to chemical exposures.
